These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
363 related articles for article (PubMed ID: 9199661)
1. The effect of antitumor trans-[PtCl2(E-iminoether)2] on B-->Z transition in DNA. Zaludová R; Natile G; Brabec V Anticancer Drug Des; 1997 Jun; 12(4):295-309. PubMed ID: 9199661 [TBL] [Abstract][Full Text] [Related]
2. DNA binding by antitumor trans-[PtCl2(NH3)(thiazole)]. Protein recognition and nucleotide excision repair of monofunctional adducts. Kasparkova J; Novakova O; Farrell N; Brabec V Biochemistry; 2003 Jan; 42(3):792-800. PubMed ID: 12534292 [TBL] [Abstract][Full Text] [Related]
3. DNA modifications by antitumor trans-[PtCl2(E-iminoether)2]. Zaludová R; Zákovská A; Kaspárkova J; Balcarová Z; Vrána O; Coluccia M; Natile G; Brabec V Mol Pharmacol; 1997 Sep; 52(3):354-61. PubMed ID: 9281596 [TBL] [Abstract][Full Text] [Related]
4. DNA binding mode of the cis and trans geometries of new antitumor nonclassical platinum complexes containing piperidine, piperazine, or 4-picoline ligand in cell-free media. Relations to their activity in cancer cell lines. Kasparkova J; Marini V; Najajreh Y; Gibson D; Brabec V Biochemistry; 2003 May; 42(20):6321-32. PubMed ID: 12755637 [TBL] [Abstract][Full Text] [Related]
5. Cytotoxicity and DNA binding mode of new platinum-iminoether derivatives with different configuration at the iminoether ligands. Boccarelli A; Coluccia M; Intini FP; Natile G; Locker D; Leng M Anticancer Drug Des; 1999 Jun; 14(3):253-64. PubMed ID: 10500500 [TBL] [Abstract][Full Text] [Related]
6. Comparison between poly(dG-dC).poly(dG-dC) and DNA modified by cis-diamminedichloroplatinum (II): immunological and spectroscopic studies. Rahmouni A; Malinge JM; Schwartz A; Leng M J Biomol Struct Dyn; 1985 Oct; 3(2):363-75. PubMed ID: 3917027 [TBL] [Abstract][Full Text] [Related]
7. DNA-protein cross-linking by trans-[PtCl(2)(E-iminoether)(2)]. A concept for activation of the trans geometry in platinum antitumor complexes. Novakova O; Kasparkova J; Malina J; Natile G; Brabec V Nucleic Acids Res; 2003 Nov; 31(22):6450-60. PubMed ID: 14602903 [TBL] [Abstract][Full Text] [Related]
8. DNA adducts of antitumor trans-[PtCl2 (E-imino ether)2]. Brabec V; Vrána O; Nováková O; Kleinwächter V; Intini FP; Coluccia M; Natile G Nucleic Acids Res; 1996 Jan; 24(2):336-41. PubMed ID: 8628659 [TBL] [Abstract][Full Text] [Related]
9. Trans-diammineplatinum(II): what makes it different from cis-DDP? Coordination chemistry of a neglected relative of cisplatin and its interaction with nucleic acids. Lippert B Met Ions Biol Syst; 1996; 33():105-41. PubMed ID: 8742842 [TBL] [Abstract][Full Text] [Related]
10. The formation of DNA interstrand cross-links by a novel bis-[Pt2Cl4(diminazene aceturate)2]Cl4.4H2O complex inhibits the B to Z transition. González VM; Fuertes MA; Jiménez-Ruíz A; Alonso C; Pérez JM Mol Pharmacol; 1999 Apr; 55(4):770-7. PubMed ID: 10101036 [TBL] [Abstract][Full Text] [Related]
11. Mechanistic studies of a novel class of trisubstituted platinum(II) antitumor agents. Hollis LS; Sundquist WI; Burstyn JN; Heiger-Bernays WJ; Bellon SF; Ahmed KJ; Amundsen AR; Stern EW; Lippard SJ Cancer Res; 1991 Apr; 51(7):1866-75. PubMed ID: 2004370 [TBL] [Abstract][Full Text] [Related]
12. Platinum(II) complexes containing iminoethers: a trans platinum antitumour agent. Coluccia M; Boccarelli A; Mariggiò MA; Cardellicchio N; Caputo P; Intini FP; Natile G Chem Biol Interact; 1995 Dec; 98(3):251-66. PubMed ID: 8548863 [TBL] [Abstract][Full Text] [Related]
13. Insights into the molecular mechanisms of protein platination from a case study: the reaction of anticancer platinum(II) iminoethers with horse heart cytochrome c. Casini A; Gabbiani C; Mastrobuoni G; Pellicani RZ; Intini FP; Arnesano F; Natile G; Moneti G; Francese S; Messori L Biochemistry; 2007 Oct; 46(43):12220-30. PubMed ID: 17924668 [TBL] [Abstract][Full Text] [Related]
14. DNA binding mode of ruthenium complexes and relationship to tumor cell toxicity. Brabec V; Nováková O Drug Resist Updat; 2006 Jun; 9(3):111-22. PubMed ID: 16790363 [TBL] [Abstract][Full Text] [Related]
15. Induction and repair of DNA cross-links in chinese hamster ovary cells treated with various platinum coordination compounds in relation to platinum binding to DNA, cytotoxicity, mutagenicity, and antitumor activity. Plooy AC; van Dijk M; Lohman PH Cancer Res; 1984 May; 44(5):2043-51. PubMed ID: 6538808 [TBL] [Abstract][Full Text] [Related]
16. DNA interactions of new antitumor platinum complexes with trans geometry activated by a 2-metylbutylamine or sec-butylamine ligand. Prokop R; Kasparkova J; Novakova O; Marini V; Pizarro AM; Navarro-Ranninger C; Brabec V Biochem Pharmacol; 2004 Mar; 67(6):1097-109. PubMed ID: 15006546 [TBL] [Abstract][Full Text] [Related]
17. Theoretical analysis on the transition state of the anticancer drug trans-[PtCl2(isopropylamine)2] and its cis isomer binding to DNA purine bases. Zhou L J Phys Chem B; 2009 Feb; 113(7):2110-27. PubMed ID: 19173577 [TBL] [Abstract][Full Text] [Related]
18. Effect of thioethers on DNA platination by trans-platinum complexes. Li C; Huang R; Ding Y; Sletten E; Arnesano F; Losacco M; Natile G; Liu Y Inorg Chem; 2011 Sep; 50(17):8168-76. PubMed ID: 21812429 [TBL] [Abstract][Full Text] [Related]
19. Unique properties of DNA interstrand cross-links of antitumor oxaliplatin and the effect of chirality of the carrier ligand. Kasparkova J; Vojtiskova M; Natile G; Brabec V Chemistry; 2008; 14(4):1330-41. PubMed ID: 18022972 [TBL] [Abstract][Full Text] [Related]
20. Reversion of structure-activity relationships of antitumor platinum complexes by acetoxime but not hydroxylamine ligands. Zorbas-Seifried S; Jakupec MA; Kukushkin NV; Groessl M; Hartinger CG; Semenova O; Zorbas H; Kukushkin VY; Keppler BK Mol Pharmacol; 2007 Jan; 71(1):357-65. PubMed ID: 17050805 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]